{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T11:34:24Z","timestamp":1648985664152},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2013,1,9]],"date-time":"2013-01-09T00:00:00Z","timestamp":1357689600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1007\/s11883-012-0303-7","type":"journal-article","created":{"date-parts":[[2013,1,8]],"date-time":"2013-01-08T23:29:25Z","timestamp":1357687765000},"source":"Crossref","is-referenced-by-count":1,"title":["Pharmacologic Interactions of Multidrug Therapy for Dyslipidemia"],"prefix":"10.1007","volume":"15","author":[{"given":"Nidhi","family":"Mehta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emil M.","family":"deGoma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,1,9]]},"reference":[{"issue":"12","key":"303_CR1","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","volume":"354","author":"JC Cohen","year":"2006","unstructured":"Cohen JC, Boerwinkle E, Mosley Jr TH, et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354(12):1264\u201372.","journal-title":"N Engl J Med"},{"issue":"15","key":"303_CR2","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa070829","volume":"356","author":"WE Boden","year":"2007","unstructured":"Boden WE, O\u2019Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356(15):1503\u201316.","journal-title":"N Engl J Med"},{"issue":"24","key":"303_CR3","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1056\/NEJMoa0805796","volume":"360","author":"RL Frye","year":"2009","unstructured":"Frye RL, August P, Brooks MM, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360(24):2503\u201315.","journal-title":"N Engl J Med"},{"issue":"6","key":"303_CR4","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/MOL.0b013e32834c7c28","volume":"22","author":"HR Davis Jr","year":"2011","unstructured":"Davis Jr HR, Tershakovec AM, Tomassini JE, et al. Intestinal sterol transporters and cholesterol absorption inhibition. Curr Opin Lipidol. 2011;22(6):467\u201378.","journal-title":"Curr Opin Lipidol"},{"issue":"1","key":"303_CR5","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.atherosclerosis.2005.06.039","volume":"186","author":"A Yamamoto","year":"2006","unstructured":"Yamamoto A, Harada-Shiba M, Endo M, et al. The effect of ezetimibe on serum lipids and lipoproteins in patients with homozygous familial hypercholesterolemia undergoing LDL-apheresis therapy. Atherosclerosis. 2006;186(1):126\u201331.","journal-title":"Atherosclerosis"},{"issue":"2","key":"303_CR6","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.atherosclerosis.2011.02.010","volume":"215","author":"HR Davis Jr","year":"2011","unstructured":"Davis Jr HR, Lowe RS, Neff DR. Effects of ezetimibe on atherosclerosis in preclinical models. Atherosclerosis. 2011;215(2):266\u201378.","journal-title":"Atherosclerosis"},{"issue":"9784","key":"303_CR7","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","volume":"377","author":"C Baigent","year":"2011","unstructured":"\u2022\u2022 Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784):2181\u201392. This study evaluated the efficacy of ezetimibe and statin combination therapy in chronic kidney disease patients.","journal-title":"Lancet"},{"issue":"12","key":"303_CR8","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1016\/j.amjcard.2009.05.003","volume":"103","author":"JG Robinson","year":"2009","unstructured":"Robinson JG, Ballantyne CM, Grundy SM, et al. Lipid-altering efficacy and safety of ezetimibe\/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study). Am J Cardiol. 2009;103(12):1694\u2013702.","journal-title":"Am J Cardiol"},{"issue":"6","key":"303_CR9","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jacl.2011.06.004","volume":"5","author":"JG Robinson","year":"2011","unstructured":"Robinson JG, Ballantyne CM, Hsueh W, et al. Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe\/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study). J Clin Lipidol. 2011;5(6):474\u201382.","journal-title":"J Clin Lipidol"},{"issue":"15","key":"303_CR10","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/j.jacc.2008.02.034","volume":"51","author":"JD Brunzell","year":"2008","unstructured":"Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol. 2008;51(15):1512\u201324.","journal-title":"J Am Coll Cardiol"},{"key":"303_CR11","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/1476-511X-10-146","volume":"10","author":"BL Abramson","year":"2011","unstructured":"Abramson BL, Benlian P, Hanson ME, et al. Response by sex to statin plus ezetimibe or statin monotherapy: a pooled analysis of 22,231 hyperlipidemic patients. Lipids Health Dis. 2011;10:146.","journal-title":"Lipids Health Dis"},{"issue":"6","key":"303_CR12","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1161\/01.CIR.99.6.736","volume":"99","author":"CM Ballantyne","year":"1999","unstructured":"Ballantyne CM, Herd JA, Ferlic LL, et al. Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy. Circulation. 1999;99(6):736\u201343.","journal-title":"Circulation"},{"issue":"9539","key":"303_CR13","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0140-6736(06)69292-1","volume":"368","author":"P Deedwania","year":"2006","unstructured":"Deedwania P, Barter P, Carmena R, et al. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet. 2006;368(9539):919\u201328.","journal-title":"Lancet"},{"issue":"4","key":"303_CR14","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1161\/CIRCULATIONAHA.104.475673","volume":"115","author":"JD Brown","year":"2007","unstructured":"Brown JD, Plutzky J. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. Circulation. 2007;115(4):518\u201333.","journal-title":"Circulation"},{"issue":"17","key":"303_CR15","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","volume":"362","author":"HN Ginsberg","year":"2010","unstructured":"\u2022\u2022 Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563\u201374. This landmark study investigated the efficacy of fenofibrate and statin combination therapy versus statin monotherapy on cardiovascular outcomes.","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"303_CR16","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.2337\/dc11-s203","volume":"34","author":"HN Ginsberg","year":"2011","unstructured":"Ginsberg HN. The ACCORD (Action to Control Cardiovascular Risk in Diabetes) Lipid trial: what we learn from subgroup analyses. Diabetes Care. 2011;34 Suppl 2:S107\u20138.","journal-title":"Diabetes Care"},{"issue":"9729","key":"303_CR17","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/S0140-6736(10)60656-3","volume":"375","author":"M Jun","year":"2010","unstructured":"Jun M, Foote C, Lv J, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet. 2010;375(9729):1875\u201384.","journal-title":"Lancet"},{"issue":"12A","key":"303_CR18","doi-asserted-by":"crossref","first-page":"29U","DOI":"10.1016\/S0002-9149(98)00732-2","volume":"82","author":"JM Morgan","year":"1998","unstructured":"Morgan JM, Capuzzi DM, Guyton JR. A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients. Am J Cardiol. 1998;82(12A):29U\u201334U. discussion 39U\u201341U.","journal-title":"Am J Cardiol"},{"issue":"3","key":"303_CR19","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1161\/ATVBAHA.111.241836","volume":"32","author":"JE Digby","year":"2012","unstructured":"Digby JE, Martinez F, Jefferson A, et al. Anti-inflammatory effects of nicotinic acid in human monocytes are mediated by GPR109A dependent mechanisms. Arterioscler Thromb Vasc Biol. 2012;32(3):669\u201376.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"303_CR20","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.amjcard.2009.10.001","volume":"105","author":"S Fazio","year":"2010","unstructured":"Fazio S, Guyton JR, Polis AB, et al. Long-term safety and efficacy of triple combination ezetimibe\/simvastatin plus extended-release niacin in patients with hyperlipidemia. Am J Cardiol. 2010;105(4):487\u201394.","journal-title":"Am J Cardiol"},{"issue":"6","key":"303_CR21","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.jacl.2010.08.020","volume":"4","author":"HE Bays","year":"2010","unstructured":"Bays HE, Shah A, Lin J, et al. Efficacy and tolerability of extended-release niacin\/laropiprant in dyslipidemic patients with metabolic syndrome. J Clin Lipidol. 2010;4(6):515\u201321.","journal-title":"J Clin Lipidol"},{"issue":"6","key":"303_CR22","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/j.1742-1241.2010.02370.x","volume":"64","author":"S Shah","year":"2010","unstructured":"Shah S, Ceska R, Gil-Extremera B, et al. Efficacy and safety of extended-release niacin\/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia. Int J Clin Pract. 2010;64(6):727\u201338.","journal-title":"Int J Clin Pract"},{"issue":"3","key":"303_CR23","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2165\/11631530-000000000-00000","volume":"12","author":"HE Bays","year":"2012","unstructured":"Bays HE, Shah A, Lin J, et al. Consistency of extended-release niacin\/laropiprant effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB\/ApoA1 ratio across patient subgroups. Am J Cardiovasc Drugs. 2012;12(3):197\u2013206.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"2","key":"303_CR24","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1177\/1074248410361337","volume":"15","author":"JK Duggal","year":"2010","unstructured":"Duggal JK, Singh M, Attri N, et al. Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease. J Cardiovasc Pharmacol Ther. 2010;15(2):158\u201366.","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"2","key":"303_CR25","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.atherosclerosis.2009.12.023","volume":"210","author":"E Bruckert","year":"2010","unstructured":"Bruckert E, Labreuche J, Amarenco P. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis. 2010;210(2):353\u201361.","journal-title":"Atherosclerosis"},{"issue":"24","key":"303_CR26","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","volume":"365","author":"WE Boden","year":"2011","unstructured":"\u2022\u2022 Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255\u201367. A landmark study that analyzed the cardiovascular outcomes of niacin therapy on top of statin therapy.","journal-title":"N Engl J Med"},{"issue":"4","key":"303_CR27","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jacl.2012.03.005","volume":"6","author":"EA Brinton","year":"2012","unstructured":"Brinton EA. Search and rescue for hypotheses surviving AIM-HIGH, the niacin therapy earthquake: still problematic after the primary publication. J Clin Lipidol. 2012;6(4):312\u20137.","journal-title":"J Clin Lipidol"},{"issue":"21","key":"303_CR28","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1056\/NEJMoa1003603","volume":"363","author":"D Kromhout","year":"2010","unstructured":"\u2022 Kromhout D, Giltay EJ, Geleijnse JM. n-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med. 2010;363(21):2015\u201326. A large-scale study examining the cardiovascular benefits of n-3 fatty acids in patients with coronary artery disease.","journal-title":"N Engl J Med"},{"issue":"9","key":"303_CR29","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1001\/archinternmed.2012.262","volume":"172","author":"SM Kwak","year":"2012","unstructured":"Kwak SM, Myung SK, Lee YJ, et al. Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: a meta-analysis of randomized, double-blind, placebo-controlled trials. Arch Intern Med. 2012;172(9):686\u201394.","journal-title":"Arch Intern Med"},{"issue":"7","key":"303_CR30","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/clc.20604","volume":"32","author":"PE Marik","year":"2009","unstructured":"Marik PE, Varon J. Omega-3 dietary supplements and the risk of cardiovascular events: a systematic review. Clin Cardiol. 2009;32(7):365\u201372.","journal-title":"Clin Cardiol"},{"issue":"4","key":"303_CR31","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1056\/NEJMoa1203859","volume":"367","author":"J Bosch","year":"2012","unstructured":"\u2022 Bosch J, Gerstein HC, Dagenais GR, et al. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med. 2012;367(4):309\u201318. This study analyzed the effect of n-3 fatty acids on cardiovascular outcomes of patients with abnormal glucose metabolism.","journal-title":"N Engl J Med"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-012-0303-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11883-012-0303-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-012-0303-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T23:49:05Z","timestamp":1559432945000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11883-012-0303-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,9]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["303"],"URL":"https:\/\/doi.org\/10.1007\/s11883-012-0303-7","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,9]]},"article-number":"303"}}